The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results.
 
Ranjana H. Advani
Consulting or Advisory Role - AstraZeneca; Bayer; Bristol-Myers Squibb; Cell Medica; Genentech/Roche; Gilead Sciences; NanoString Technologies; Pharmacyclics; Seagen; Spectrum Pharmaceuticals; Sutter Medical Group
Research Funding - Agensys (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Kura Oncology (Inst); Merck (Inst); Millennium (Inst); Pharmacyclics (Inst); Regeneron (Inst); Seagen (Inst)
 
Ian Flinn
Stock and Other Ownership Interests - RainTree Oncology Services
Research Funding - Acerta Pharma (Inst); Agios (Inst); Calithera Biosciences (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunogen (Inst); Incyte (Inst); Infinity Pharmaceuticals (Inst); Janssen (Inst); Karyopharm Therapeutics (Inst); Kite, a Gilead company (Inst); Medivation (Inst); Millennium (Inst); Novartis (Inst); OncoMed (Inst); Pharmacyclics (Inst); Portola Pharmaceuticals (Inst); Roche (Inst); Seagen (Inst); TG Therapeutics (Inst); Trillium Therapeutics (Inst)
 
Leslie Popplewell
Honoraria - AstraZeneca; Cardinal Health
 
Andres Forero-Torres
Research Funding - Forty Seven (Inst); Gilead Sciences (Inst); Incyte (Inst); Juno Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); Seagen (Inst); Syndax (Inst)
 
Nancy L. Bartlett
Consulting or Advisory Role - Kite, a Gilead company; Pfizer; Seagen
Research Funding - Affimed Therapeutics (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dynavax Technologies (Inst); Forty Seven (Inst); Genentech (Inst); Gilead Sciences (Inst); Idera (Inst); Immune Design (Inst); Incyte (Inst); Janssen (Inst); Kite, a Gilead company (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Pharmacyclics (Inst); Seagen (Inst)
 
Nilanjan Ghosh
Consulting or Advisory Role - Janssen; Juno Therapeutics; Kite, a Gilead company; Spectrum Pharmaceuticals
Speakers' Bureau - Abbvie; Celgene; Gilead Sciences; Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Celgene (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Janssen (Inst); Juno Therapeutics (Inst); Pharmacyclics (Inst); Seagen (Inst); TG Therapeutics (Inst)
 
Justin Paul Kline
Consulting or Advisory Role - Merck
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck
 
Thu Tran
No Relationships to Disclose
 
Judith Lynn
Employment - Forty Seven
 
James Y Chen
Employment - Forty Seven
Patents, Royalties, Other Intellectual Property - Stanford University
 
Balaji Agoram
Employment - Forty Seven; MedImmune
Stock and Other Ownership Interests - Forty Seven
 
Jenny Huang
Employment - Forty Seven; Genentech
Stock and Other Ownership Interests - Forty Seven; Genentech
 
Chris H.M. Takimoto
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven; Johnson & Johnson
Patents, Royalties, Other Intellectual Property - Patent Proposals filed relating to using anti-CD47 antibodies as cancer therapy at my current company of employment, Forty Seven, Inc.
Travel, Accommodations, Expenses - Forty Seven
 
Mark Chao
Employment - Forty Seven
Leadership - Forty Seven
Stock and Other Ownership Interests - Forty Seven
Research Funding - Forty Seven
Patents, Royalties, Other Intellectual Property - Forty Seven
Travel, Accommodations, Expenses - Forty Seven
 
Sonali M. Smith
Consulting or Advisory Role - Abbvie/Genentech; Amgen; AstraZeneca; Celgene; Forty Seven; Genmab; Gilead Sciences; Juno Therapeutics; Kite, a Gilead company; NanoString Technologies; Pharmacyclics; Portola Pharmaceuticals; Roche; TG Therapeutics